Investigational drugs for neuroendocrine tumours

Expert Opinion on Investigational Drugs

Volumn 18, Issue 5, 2009, Pages 601-608

  Granberg, Dan ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Angiogenesis inhibitors; Chemotherapy; mTOR inhibitors; Neuroendocrine tumours; Radioembolization; Targeted receptor therapy; Tyrosine kinase receptor inhibitors

Indexed keywords

ALPHA INTERFERON; AMG 479; ANGIOGENESIS INHIBITOR; BIM 23A760; BORTEZOMIB; CAPECITABINE; CISPLATIN; DACARBAZINE; DEXTRO PHENYLALANYLCYSTEINYLTYROSYL DEXTRO TRYPTOPHYLLYSYLVALYLCYSTEINYLTHREONINAMIDE 2,7 DISULFIDE 2 PYRROLINODOXORUBICIN; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; EVEROLIMUS; FLUOROURACIL; GEFITINIB; GEMCITABINE; IMATINIB; IRINOTECAN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; OCTREOTIDE; OXALIPLATIN; PACLITAXEL; PASIREOTIDE; PEMETREXED; SOMATOSTATIN DERIVATIVE; SORAFENIB; STREPTOZOCIN; TEMOZOLOMIDE; TOPOTECAN; TYROSINE KINASE RECEPTOR; TYROSINE KINASE RECEPTOR INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG;

CANCER CHEMOTHERAPY; DIARRHEA; DRUG CYTOTOXICITY; DRUG MECHANISM; DRUG SCREENING; FLUSHING; GASTROINTESTINAL TUMOR; HUMAN; ISOTOPE LABELING; LUNG TUMOR; NEUROENDOCRINE TUMOR; PANCREAS CANCER; PANCREAS CARCINOMA; PANCREAS TUMOR; REVIEW; THYMOMA;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; DRUGS, INVESTIGATIONAL; HUMANS; NEUROENDOCRINE TUMORS; PROTEIN KINASE INHIBITORS;

EID: 67649576632     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543780902850432     Document Type: Review

References (58)

1. Klöppel G, Perren A, Heitz PU. The gastroenteropancreatic neuroendocrine cell system and its tumors: the WHO classification. Scintigrafi 2004;1014:13-27 (Pubitemid 38594787)
2. Öberg K. Chemotherapy and biotherapy in the treatment of neuroendocrine tumours. Ann Oncol 2001;12(Suppl 2):111-114 (Pubitemid 33069698)
3. Garland J, Buscombe JR, Bouvier C, et al. Sandostatin LAR (long-acting octreotide acetate) for malignant carcinoid syndrome: a 3-year experience. Aliment Pharmacol Ther 2003;17:437-444
4. Ruszniewski P, Ish-Shalom S, Wymenga M, et al. Rapid and sustained relief from the symptoms of carcinoid syndrome: results from an open 6-month study of the 28-day prolonged-release formulation of lanreotide. Neuroendocrinology 2004;80:244-251
5. Schmid HA, Schoeffter P. Functional activity of the multiligand analog SOM230 at human recombinant somatostatin receptor subtypes supports its usefulness in neuroendocrine tumors. Neuroendocrinology 2004;80(Suppl 1):47-50 (Pubitemid 39382369)
6. Kvols L, Wiedenmann B, Öberg K, et al. Safety and efficacy of pasireotide (SOM230) in patients with metastatic carcinoid tumors refractory or resistant to octreotide LAR: results of a phase II study. J Clin Oncol 2006;24(18S):4082 •• This is the first report of the superior symptomatic effect of SOM-230, pasireotide, in carcinoid patients
7. Pasquali D, Rossi V, Conzo G, et al. Effects of somatostatin analog SOM230 on cell proliferation, apoptosis, and catecholamine levels in cultured pheochromocytoma cells. J Mol Endocrinol 2008;40:263-271 (Pubitemid 351865034)
8. Kidd M, Schally AV, Pfragner R, et al. Inhibition of proliferation of small intestinal and bronchopulmonary neuroendocrine cell lines by using peptide analogs targeting receptors. Cancer 2008;112:1404-1414 • This is a preclinical study of targeted receptor inhibition with peptide analogues.
9. Jaquet P, Gunz G, Saveanu A, et al. BIM-23A760, a chimeric molecule directed towards somatostatin and dopamine receptors, vs universal somatostatin receptors ligands in GH-secreting pituitary adenomas partial responders to octreotide. J Endocrinol Invest 2005;28(11 Suppl International):21-27
10. Jaquet P, Gunz G, Saveanu A, et al. Efficacy of chimeric molecules directed towards multiple somatostatin and dopamine receptors on inhibition of GH and prolactin secretion from GH-secreting pituitary adenomas classified as partially responsive to somatostatin analog therapy. Eur J Endocrinol 2005;153:135-141 (Pubitemid 41030524)
11. Kouvaraki MA, Ajani JA, Hoff P, et al. Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J Clin Oncol 2004;22:4762-71. Erratum in: J Clin Oncol 2005;23:248 (Pubitemid 41185087)
12. Fjallskog ML, Janson ET, Falkmer UG, et al. Treatment with combined streptozotocin and liposomal doxorubicin in metastatic endocrine pancreatic tumors. Neuroendocrinology 2008;88:53-58
13. Guigay J, Ruffié P, Leboulleux S, et al. Response of atypical pulmonary carcinoid tumors to chemotherapy. A retrospective study of 37 patients. J Thorac Oncol 2007;2(Suppl 4):S599
14. Granberg D, Eriksson B, Wilander E, et al. Experience in treatment of metastatic pulmonary carcinoid tumors. Ann Oncol 2001;12:1383-1391
15. Moertel CG, Kvols LK, O'Connell MJ, Rubin J. Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer 1991;68:227-232
16. Mitry E, Baudin E, Ducreux M, et al. Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin. Br J Cancer 1999;81:1351-1355
17. Fjällskog ML, Granberg DP, Welin SL, et al. Treatment with cisplatin and etoposide in patients with neuroendocrine tumors. Cancer 2001;92:1101-1107
18. Kulke MH, Wu B, Ryan DP, et al. A phase II trial of irinotecan and cisplatin in patients with metastatic neuroendocrine tumors. Dig Dis Sci 2006;51:1033-1038 • This paper reports that a combination of cisplatin and irinotecan may be active in patients with high-grade neuroendocrine tumours.
19. Mani MA, Shroff RT, Jacobs C, et al. A phase II study of irinotecan and cisplatin for metastatic or unresectable high grade neuroendocrine carcinoma. J Clin Oncol 2008;26(15S):15550 • This report confirms the efficacy of cisplatin and irinotecan in patients with high-grade neuroendocrine tumours.
20. Bajetta E, Catena L, Procopio G, et al. Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumours? Cancer Chemother Pharmacol 2007;59:637-642 • This study describes a new chemotherapy combination for patients with low-proliferative neuroendocrine tumours.
21. Bajetta E, Ferrari L, Procopio G, et al. Efficacy of a chemotherapy combination for the treatment of metastatic neuroendocrine tumours. Ann Oncol 2002;13:614-621
22. Ekeblad S, Sundin A, Tiensuu Janson E, et al. Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors. Clin Cancer Res 2007;13:2986-2991
23. Kulke MH, Frauenhoffer CS, Hooshmand CM, et al. Prediction of response to temozolomide (TMZ)-based therapy by loss of MGMT expression in patients with advanced neuroendocrine tumors (NET). J Clin Oncol 2007;25(18S):4505
24. Isacoff WH, Moss RA, Pecora AL, Fine RL. Temozolomide/capecitabine therapy for metastatic neuroendocrine tumors of the pancreas. A retrospective review. J Clin Oncol 2006;247(18S):14023 • This is an interesting report of combination chemotherapy in patients with neuroendocrine tumours.
25. Ansell SM, Pitot HC, Burch PA, et al. A Phase II study of high-dose paclitaxel in patients with advanced neuroendocrine tumors. Cancer 2001;91:1543-1548
26. Kulke MH, Kim H, Stuart K, et al. A phase II study of docetaxel in patients with metastatic carcinoid tumors. Cancer Invest 2004;22:353-359
27. Kulke MH, Kim H, Clark JW, et al. A Phase II trial of gemcitabine for metastatic neuroendocrine tumors. Cancer 2004;101:934-939
28. Ansell SM, Mahoney MR, Green EM, Rubin J. Topotecan in patients with advanced neuroendocrine tumors: a phase II study with significant hematologic toxicity. Am J Clin Oncol 2004;27:232-235 (Pubitemid 38737795)
29. Bhargava P, Earle CC, Zhu AX, et al. A phase II study of pemetrexed in patients (pts) with advanced neuroendocrine tumors (NETs). J Clin Oncol 2007;25(18S):15149
30. Larsson DE, Lövborg H, Rickardson L, et al. Identification and evaluation of potential anti-cancer drugs on human neuroendocrine tumor cell lines. Anticancer Res 2006;26(6B):4125-4129 • This is a preclinical study aiming at finding new active drugs in patients with neuroendocrine tumours.
31. Welin S, Fjallskog ML, Saras J, et al. Expression of tyrosine kinase receptors in malignant midgut carcinoid tumors. Neuroendocrinology 2006;84:42-48
32. Granberg D, Wilander E, Öberg K. Expression of tyrosine kinase receptors in lung carcinoids. Tumor Biol 2006;27:153-157
33. Fjällskog ML, Lejonklou MH, Öberg KE, et al. Expression of molecular targets for tyrosine kinase receptor antagonists in malignant endocrine pancreatic tumors. Clin Cancer Res 2003;9:1469-1473
34. Papouchado B, Erickson LA, Rohlinger AL, et al. Epidermal growth factor receptor and activated epidermal growth factor receptor expression in gastrointestinal carcinoids and pancreatic endocrine carcinomas. Mod Pathol 2005;18:1329-1335
35. Shah T, Hochhauser D, Frow R, et al. Epidermal growth factor receptor expression and activation in neuroendocrine tumours. J Neuroendocrinol 2006;18:355-360
36. Gross DJ, Munter G, Bitan M, et al. The role of imatinib mesylate (Glivec) for treatment of patients with malignant endocrine tumors positive for c-kit or PDGF-R. Endocr Relat Cancer 2006;13:535-540
37. Yao JC, Zhang JX, Rashid A, et al. Clinical and in vitro studies of imatinib in advanced carcinoid tumors. Clin Cancer Res 2007;13:234-240
38. Hobday TJ, Rubin J, Holen K, et al. MC044h, a phase II trial of sorafenib in patients (pts) with metastatic neuroendocrine tumors (NET): a Phase II Consortium (P2C) study. J Clin Oncol 2007;25(18S):4504
39. Kulke MH, Lenz HJ, Meropol NJ, et al. Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol 2008;26:3403-3410 •• This is an interesting study showing the efficacy and tolerability of sunitinib, a tyrosine kinase inhibitor, in patients with neuroendocrine tumours.
40. Hobday TJ, Mahoney M, Erlichman C, et al. Preliminary results of a phase II trial of Gefitinib in progressive metastatic neuroendocrine tumors (NET): a phase II consortium PC2) study. J Clin Oncol 2005;23(16S):4083
41. Tolcher AW, Rothenberg ML, Rodon J, et al. A phase I pharmacokinetic and pharmacodynamic study of AMG 479, a fully human monoclonal antibody against insulin-like growth factor type 1 receptor (IGF-1R), in advanced solid tumors. J Clin Oncol 2007;25(18S):3002 • This is an interesting study using an antibody against IGF-1 receptor.
42. Shah MH, Young D, Kindler HL, et al. Phase II study of the proteasome inhibitor bortezomib (PS-341) in patients with metastatic neuroendocrine tumors. Clin Cancer Res 2004;10:6111-6118
43. Shah MH, Binkley P, Chan K, et al. Cardiotoxicity of histone deacetylase inhibitor depsipeptide in patients with metastatic neuroendocrine tumors. Clin Cancer Res 2006;12:3997-4003
44. Vignot S, Faivre S, Aguirre D, Raymond E. mTOR-targeted therapy of cancer with rapamycin derivatives. Ann Oncol 2005;16:525-537 (Pubitemid 40613318)
45. Duran I, Kortmansky J, Singh D, et al. A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas. Br J Cancer 2006;95:1148-1154 (Pubitemid 44660065)
46. Moreno A, Akcakanat A, Munsell MF, et al. Antitumor activity of rapamycin and octreotide as single agents or in combination in neuroendocrine tumors. Endocr Relat Cancer 2008;15:257-266 •• This is a preclinical and clinical study showing antitumoural effect of sirolimus, an mTOR antagonist.
47. Yao JC, Phan AT, Chang DZ, et al. Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study. J Clin Oncol 2008;26:4311-4318 •• This report shows the antitumoural effect of everolimus in patients with neuroendocrine tumours.
48. Terris B, Scoazec JY, Rubbia L, et al. Expression of vascular endothelial growth factor in digestive neuroendocrine tumours. Histopathology 1998;32:133-138
49. O'Reilly MS, Boehm T, Shing Y, et al. Endostatin: An endogenous inhibitor of angiogenesis and tumor growth. Cell 1997;88:277-285
50. Kulke MH, Bergsland EK, Ryan DP, et al. Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumors. J Clin Oncol 2006;24:3555-3561 (Pubitemid 46630526)
51. Yao JC, Phan A, Hoff PM, et al. Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. J Clin Oncol 2008;26:1316-1323
52. Sung M, Kvols L, Jacob G, et al. Phase II proof-of-concept study of atiprimod in patients with advanced low- to intermediate-grade neuroendocrine carcinoma. J Clin Oncol 2008;26(15S):4611 •• This study of a new agent with antiangiogenic and pro-apoptotic properties is of great interest.
53. Kulke MH, Stuart K, Enzinger PC, et al. Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J Clin Oncol 2006;24:401-406 • This paper reports that antiangiogenic therapy may be effective in neuroendocrine tumour patients. (Pubitemid 46630459)
54. Kulke M, Stuart K, Earle CC, et al. A phase II study of temozolomide and bevacizumab in patients with advanced neuroendocrine tumors. J Clin Oncol 2006;24(18S):4044 •• This is an interesting study of combination of a cytotoxic agent and an antiangiogenic drug.
55. Kunz PL, Kuo T, Kaiser HL, et al. A phase II study of capecitabine, oxaliplatin, and bevacizumab for metastatic or unresectable neuroendocrine tumors: preliminary results. J Clin Oncol 2008;26(15S):15502 •• This is another report of efficacy and tolerability of combination of cytotoxic and antiangiogenic drugs.
56. Kwekkeboom DJ, Mueller-brand J, Paganelli G, et al. Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs. J Nucl Med 2005;46(Suppl 1):62-66 • This paper reviews the results of treatment with radiolabelled somatostatin analogues. (Pubitemid 47619020)
57. Kwekkeboom DJ, de Herder WW, Kam BL, et al. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol 2008;26:2124-2130 •• This is a comprehensive evaluation of treatment with 177Lu-octreotate in patients with neuroendocrine tumours.
58. Kennedy AS, Dezarn WA, McNeillie P, et al. Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-microspheres: early results in 148 patients. Am J Clin Oncol 2008;31:271-279 •• This paper reports the results of radioembolization in patients with neuroendocrine tumours.